Developing treatments for rare diseases is already risky and expensive, and the COVID-19 pandemic made it even harder — disrupting clinical trials and slowing down research timelines. This bill, named "Leo's Law," would give orphan drug developers (companies working on treatments for rare diseases) an extra 180 days of market exclusivity to make up for pandemic-related delays. That means more time before generic or biosimilar competitors can enter the market, which could help incentivize continued investment in treatments that often serve very small patient populations.
Congressional Summary
Leo's Law This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.
Details
- Congress
- 119th
- Chamber
- House
- Status
- summarized
- Action
- Introduced in House
- Action Date
- 2026-02-25
- Date Added
- 2026-04-06